Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study
出版年份 2017 全文链接
标题
Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study
作者
关键词
-
出版物
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 58, Issue 4, Pages 504-513
出版商
Wiley
发表日期
2017-12-14
DOI
10.1002/jcph.1042
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials
- (2017) Glenwood Goss et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
- (2016) David Planchard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
- (2016) J. Yang et al. Journal of Thoracic Oncology
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
- (2014) Wei Li et al. LUNG CANCER
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
- (2014) J.L. Kuiper et al. LUNG CANCER
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients
- (2013) Yayi He et al. LUNG CANCER
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
- (2011) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started